1. Home
  2. KRYS vs ELPC Comparison

KRYS vs ELPC Comparison

Compare KRYS & ELPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • ELPC
  • Stock Information
  • Founded
  • KRYS 2015
  • ELPC 1954
  • Country
  • KRYS United States
  • ELPC Brazil
  • Employees
  • KRYS N/A
  • ELPC N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • ELPC Electric Utilities: Central
  • Sector
  • KRYS Health Care
  • ELPC Utilities
  • Exchange
  • KRYS Nasdaq
  • ELPC Nasdaq
  • Market Cap
  • KRYS 4.5B
  • ELPC 3.9B
  • IPO Year
  • KRYS 2017
  • ELPC N/A
  • Fundamental
  • Price
  • KRYS $148.39
  • ELPC $5.43
  • Analyst Decision
  • KRYS Strong Buy
  • ELPC
  • Analyst Count
  • KRYS 7
  • ELPC 0
  • Target Price
  • KRYS $206.67
  • ELPC N/A
  • AVG Volume (30 Days)
  • KRYS 292.3K
  • ELPC 4.6K
  • Earning Date
  • KRYS 02-24-2025
  • ELPC 01-01-0001
  • Dividend Yield
  • KRYS N/A
  • ELPC 5.03%
  • EPS Growth
  • KRYS N/A
  • ELPC 43.89
  • EPS
  • KRYS 1.77
  • ELPC 0.19
  • Revenue
  • KRYS $241,519,000.00
  • ELPC $4,076,906,276.00
  • Revenue This Year
  • KRYS $485.65
  • ELPC N/A
  • Revenue Next Year
  • KRYS $58.64
  • ELPC $7.60
  • P/E Ratio
  • KRYS $83.69
  • ELPC $7.61
  • Revenue Growth
  • KRYS 2722.80
  • ELPC 4.83
  • 52 Week Low
  • KRYS $107.50
  • ELPC $5.04
  • 52 Week High
  • KRYS $219.34
  • ELPC $7.74
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 37.81
  • ELPC 51.65
  • Support Level
  • KRYS $141.72
  • ELPC $5.31
  • Resistance Level
  • KRYS $152.94
  • ELPC $5.44
  • Average True Range (ATR)
  • KRYS 5.22
  • ELPC 0.09
  • MACD
  • KRYS -0.42
  • ELPC 0.04
  • Stochastic Oscillator
  • KRYS 33.00
  • ELPC 84.80

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))

Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Holding and Services. Majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.

Share on Social Networks: